Investor Relations

Eton Pharmaceuticals, Inc. is a commercial company focused on developing, acquiring, and commercializing high-potential therapies for the treatment of patients with rare diseases. We have a diversified pipeline of product candidates across multiple therapeutic areas, and a team with significant expertise in bringing products from clinical trials to patients with exceptional speed.

Volume :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
September 13, 2022
-- Expected to be accretive to 2023 earnings -- DEER PARK, Ill. , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the
August 30, 2022
DEER PARK, Ill. , Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen , Chief Executive Officer, will
August 11, 2022
Total Q2 2022 revenue of $7.4 million , up 139% from prior year Recently launched ALKINDI SPRINKLE ® and Carglumic Acid continue to show robust growth Divestiture of hospital products division to focus on rare disease strategy U.S. Food and Drug Administration (FDA) Approval of Zonisade™